BUZZ-Nicox: Jumps on study results
** French ophthalmic company's shares up 11 pct on study phase 3 positive results
** Reported with Bausch + Lomb that latanoprostene bunod (LBN) ophthalmic solution 0.024 pct phase 3 study demonstrates significantly greater efficacy versus Timolol maleate 0.5 pct
** Stock on track for best day in >6 mo
** By far top performer of Euronext Next 150 (-0.5 pct)
© Thomson Reuters 2017 All rights reserved.